U.S., Aug. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07131683) titled 'hUC-MSC-Exo Therapy for Autoimmune Encephalitis' on Aug. 07.

Brief Summary: This is a phase I/IIa study to investigate the safety and preliminary efficacy of intranasal admnistration of human umbilical mesenchymal stem cell-derived exosome (hUC-MSC-Exo) for patients with autoimmune encephalitis.

Study Start Date: Nov. 01, 2025

Study Type: INTERVENTIONAL

Condition: Autoimmune Encephalitis

Intervention: BIOLOGICAL: Human umbilical cord mesenchymal stem cell derived exosomes

Nasal spray of hUC-MSC-Exo (low dose: 2.5x10^10 particles, mid-dose: 5.0x10^10 particles, high-dose: 1.0x10^11 particles), once per day for 7 days, then onc...